PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
13.58
Current Ratio 1.25–1.5x CRVO's 11.59. Bruce Berkowitz might see stronger short-term risk mitigation vs. competitor.
13.58
Quick Ratio 1.25–1.5x CRVO's 11.59. Bruce Berkowitz sees this as a distinct advantage in times of tight credit.
13.39
Cash Ratio above 1.5x CRVO's 2.90. David Dodd would confirm if this large cash position offsets potential expansions or acquisitions.
-30.15
Negative interest coverage while CRVO shows 0.00. Joel Greenblatt would look for earnings improvements and debt restructuring catalysts.
-14.65
Negative short-term coverage while CRVO shows 0.00. Joel Greenblatt would look for cash flow improvements and refinancing catalysts.